AOD-9604 AOD-9604 is a peptide made from a modified fragment of human growth hormone (HGH)
EMA Decision P/0336/2024 Paediatric Investigation Plan for retatrutide
Received: Accepted: Published: Version of record: DOI:
Heres what you need to know: Mechanism: Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through beta-3 adrenergic receptor modulation and direct adipocyte interaction Primary Benefit: Enhanced fat metabolism and body composition improvement without affecting blood sugar or insulin sensitivity Administration: Subcutaneous injection or oral administration, typically daily Typical Dosing: 250-500 mcg daily via injection, or higher doses (1-2 mg) orally, administered in morning on empty stomach Results Timeline: Initial metabolic changes within 2-4 weeks, visible body composition changes in 8-12 weeks Best For: Individuals seeking metabolic support, stubborn fat reduction, and body recomposition without growth hormone effects Safety Profile: Clinical trials with over 900 participants demonstrated excellent tolerability with no serious adverse events Comparison: More selective than full-length growth hormone, targeting only fat metabolism without affecting glucose regulation or IGF-1 levels The following guide provides complete details on AOD-9604 s metabolic support process, from molecular mechanisms to practical protocols
This oral peptide is particularly effective for individuals with: Excess visceral (abdominal) fat Metabolic syndrome or insulin resistance Age-related NAD+ decline Fat loss goals while preserving muscle mass GLP-1 users who want to offset muscle loss Its also ideal for people who: Prefer oral therapy over injections Travel frequently and need convenience Want a well-tolerated fat loss support with no stimulant effects How It Compares to Other Peptides Side Effects and Safety To date, no harmful side effects have been reported with oral 5-Amino-1MQ in either animal studies or clinical use
Food and Drug Administration) FDA meeting materials indicate FDA proposed that certain AOD-9604 forms not be included on the 503A bulks list at that time
